#ESMO24 Quick Take Insights: A Focus on the #PEACE3Study PEACE-3 shows that combining radium-223 with enzalutamide boosts rPFS and OS in first-line #mCRPC with bone metastases. Notably, this combo, alongside bone-protective agents, may now be a viable 1st-line treatment for mCRPC

Topline results from BOND-003 cohort P – A multinational, single-arm study of intravesical cretostimogene grenadenorepvec for treatment of high-risk, papillary-only, BCG-unresponsive #NMIBC. Presentation by @MarkTysonMD @MayoClinic. #SUO25 written coverage by @RKSayyid @UAUrology

Primary efficacy and surgical details in #KEYNOTE905: Neoadjuvant and adjuvant enfortumab vedotin + pembrolizumab in participants with muscle-invasive #BladderCancer who are cisplatin-ineligible. Presented by Hristos Kaimakliotis, MD @IUCancerCenter. #SUO25 written coverage by

First results from CORE-008 cohort A – A phase 2 study of intravesical cretostimogene grenadenorepvec in patients with high-risk, BCG-naïve, #NMIBC. Presentation by @tbivala1 @PennMedicine. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/KH9Xy60FvR @UroOnc

INLEXZO™ monotherapy in patients with BCG-unresponsive papillary disease-only, high-risk #NMIBC: 1-year disease-free survival results from #SunRISe1. Presentation by @siadaneshmand @KeckMedicineUSC. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/fOzs5F0i6k

Baseline urinary tumor DNA, minimal residual disease, and genomic disease burden in relation to clinical response to TAR-200 in the phase 2b SunRISe-1 trial. Presentation by @GSK_UofT @UofTUrology. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/PsMtc8tilQ @UroOnc

ctDNA for MRD assessment in #MIBC: Evidence and evolving practice. Presentation by Matt Galsky, MD @TischCancer. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/kCU9NJL67n @UroOnc #SUO2025

#SUO25 LBA KEYNOTE-905: Perioperative EV + pembro in cis-ineligible MIBC 🔹Time from EV+P comp➡️RC: 5.6 wks 🔹EFS, OS, pCR all significantly improved vs RC alone 🚨pCR: 57.1% vs 8.6% 🔹24-mo EFS: 75% vs 39% 🔹24-mo OS: 80% vs 63% 🔹Neoadj EVP did NOT delay or impair RC

#SUO25 LBA SunRISe-1 Cohort 4: Gem-iDRS (TAR-200) in BCG-UR papillary-only HR-NMIBC (n=52; f/u: 16 mo) 🔹12-mo DFS: 74.3% 🔹HG Ta: 74.8% | HG T1: 74.1% 🔹PFS @12 mo: 95.6% 🔹OS @12 mo: 98% 🔹RC-free survival: 91% 🔹Only 1 MIBC progression; median DFS not reached 📛Well

#SUO25 LBA CORE-008 Cohort A: Cretostimogene in HR BCG-naïve NMIBC (n=54; f/u: 5.6 mo) 🔹CR: 83.7% (95% CI 70.3–92.7) 🔹Original admin (5-step): 79.2% vs Optimized (2-step): 88% 🔹No RCs, no MIBC/metastatic progression 🔹98.1% completed all protocol treatments 📛0% Grade ≥3

Precystectomy ctDNA burden is predictive of poor oncological outcomes. Presentation by @ahmederaky @MountSinaiNYC. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/9dU6ooQrzO @Uroweb #SUO2025

#SUO25 BOND-003 Cohort P: Intravesical cretostimogene for HR, papillary-only BCG-unresponsive NMIBC (n=56; median f/u: 6 mo) 🔹HG-EFS (Ta): 92.8% @3m, 75.9% @6m & 9m 🔹HG-EFS (T1): 100% @3m & 6m, 87.5% @9m 🔹0 RCs, 0 MIBC progression 🔹98.2% completed protocol; no Grade ≥3 TRAEs

Neuropathy guides clinical decision-making and predicts survival in first-line enfortumab vedotin + pembrolizumab for metastatic #UrothelialCarcinoma. Presentation by Ahmet Yildirim, MD @InovaHealth. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/7f0m008ckz

From radical to reasonable? The decline in overtreatment of low-risk #ProstateCancer. Presentation by @tudor_borza @UMichUrology. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/ipzKqLaoyP @UroOnc #SUO2025

MRD detection in #NMIBC: The role of utDNA and clinical implications. Presentation by @UrogerliMD @MoffittNews. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/hhU2MuABBb @UroOnc #SUO2025

Living well with #ProstateCancer: A randomized de-implementation trial targeting overuse of hormonal treatment for #ProstateCancer. Presentation by Ted Skolarus, MD, MPH @UChicago. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/Tj1uaZhNPj @UroOnc #SUO2025

Healthcare resource utilization and medical costs in patients with metastatic castration sensitive prostate cancer initiating apalutamide or darolutamide in the United States. Presented by Sabree Burbage, PharmD, MPH. #SUO25 written coverage by @chavarriagaj @PSH_Urology on

Technical advances, challenges, and future directions in liquid biopsy MRD assays. Presentation by @G_Vandekerkhove @VanProstateCtr. #SUo25 written coverage by @chavarriagaj @PSH_Urology on UroToday > https://t.co/CbfwxvWlXR @UroOnc